Using Al18F-octreotide PET/CT for Neuroendocrine Tumors
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
This study is testing a new type of imaging called Al18F-octreotide PET/CT to see if it can help doctors better diagnose neuroendocrine tumors in patients who may have them.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Locations | 1 site (Beijing, Chao Yang) |
| Trial ID | NCT05749289 on ClinicalTrials.gov |
What this trial studies
This open-label study investigates the effectiveness of Al18F-octreotide PET/CT imaging in diagnosing neuroendocrine tumors. It focuses on patients with suspected or diagnosed neuroendocrine tumors, utilizing a non-invasive imaging method to enhance diagnostic accuracy. The study aims to provide clear imaging for clinical diagnosis and treatment planning, leveraging the high sensitivity and specificity of octreotide in detecting tumor cells. By employing this advanced imaging technique, the research seeks to contribute to the field of positron imaging in medicine.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with suspected or clearly diagnosed neuroendocrine tumors who can provide informed consent.
Not a fit: Patients who are pregnant, breastfeeding, or have medical conditions that may interfere with study compliance will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the accuracy of diagnosing neuroendocrine tumors, leading to better treatment outcomes for patients.
How similar studies have performed: Other studies have shown promising results with similar imaging approaches, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with suspected or clearly diagnosed SSTR positive tumors * signed written consent. * Willing and able to cooperate with all projects in this study. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Where this trial is running
Beijing, Chao Yang
- National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Chao Yang, China (Recruiting)
Study contacts
- Study coordinator: Gouzhu Hou, M.D.
- Email: 15611145656@163.com
- Phone: 15611145656
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.